Quality assessment criteria for economic evaluations included in the review
| Dimension of quality | Reported (study reference in online supplementary table S2) | Not reported (study reference in online supplementary table S2) | Note |
|---|---|---|---|
| A clear description of the study objective and comparators is provided | 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64 | 52 | 52: Not clearly stated |
| Characteristics of target population and subgroups are described and analysed | 1, 2, 3, 4, 6, 8, 9, 10, 11, 12, 13, 15, 16, 17, 18, 19, 20, 21, 23, 24, 25, 26, 27, 28, 29, 30, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64 | 5, 7, 14, 22, 31 | 55: Reference for target population given; 22: only stated no difference between groups |
| Setting and location of the study is stated | 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64 | ||
| Study perspective is clearly stated | 6, 7, 8, 10, 12, 13, 27, 54, 56, 58, 60, 63 | 1, 2, 3, 4, 5, 9, 11, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 55, 57, 59, 61, 62, 64 | 7: Has only healthcare payer costs; 12: not what is stated; 60: not what is stated |
| Time horizon of costs and benefits is clear | 1, 2, 3, 4, 5, 6, 7, 9, 10, 11, 12, 13, 14, 15, 16, 17, 19, 20, 21, 22, 23, 26, 27, 28, 30, 31, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 44, 45, 46, 47, 49, 50, 51, 53, 54, 55, 56, 57, 58, 60, 61, 62, 63, 64 | 8, 18, 24, 25, 29, 32, 43, 48, 52, 59 | |
| Discount rate is stated or an explanation is given if costs or benefits are not discounted (where applicable) | 4, 5, 6, 10, 12, 13, 14, 27, 54, 55 | 3, 7, 15, 51 | 5, 54, 13: Benefits only |
| Source and methods used to collect effectiveness data described | 1, 2, 3, 4, 5, 6, 7, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64 | 8 | 8: Not clear |
| The primary outcome measure(s) for economic evaluation are clearly stated | 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64 | ||
| Quantities of resources are reported separately from their unit costs | 6, 7, 10, 11, 12, 54, 55, 54, 56, | 1, 2, 3, 4, 5, 8, 9, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 57, 58, 59, 60, 61, 62, 63, 64 | 7: Only unit costs reported separately, 55 ref to web table given |
| Approaches used to estimate resource use and cost are clear | 1, 2, 3, 4, 5, 6, 7, 8, 10, 11, 12, 13, 14, 15, 16, 17, 19, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64 | 9, 18, 20, 21 | |
| Cost components clear | 6, 7, 10, 11, 12, 14, 42, 54, 55, 56 | 1, 2, 3, 4, 5, 8, 9, 13, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 57, 58, 59, 60, 61, 62, 63, 64 | |
| Currency/price year are explicitly stated | 2, 4, 5, 6, 9, 10, 12, 14, 19, 20, 26, 27, 29, 32, 35, 37, 40, 41, 43, 45, 47, 50, 51, 53, 54, 55, 58, 61, 62, 63 | 1, 3, 7, 8, 11, 13, 15, 16, 17, 18, 21, 22, 23, 24, 25, 28, 30, 31, 34, 33, 36, 38, 39, 42, 44, 46, 48, 49, 52, 56, 57, 59, 60, 64 | |
| Analytic methods supporting the evaluation including methods for dealing with skewed, missing or censored data, extrapolation methods, methods for pooling data, approaches to validate or make adjustments to a model, methods for handling population heterogeneity and uncertainty described in details | 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64 | 7, 13, 14 | |
| Incremental costs and outcomes reported (if applicable, incremental cost-effectiveness ratios reported) | 2, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 26, 41, 48, 54, 55, 56 | 1, 3, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 49, 50, 51, 52, 53, 57, 58, 59, 60, 61, 62, 63, 64 | 11: Only in graphs |
| Sensitivity analysis carried out | 1, 4, 5, 6, 7, 8, 10, 11, 12, 13, 14, 27, 33, 42, 45, 54, 55, 57, 60 | 2, 3, 9, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 28, 29, 30, 31, 32, 34, 35, 36, 37, 38, 39, 40, 41, 43, 44, 46, 47, 48, 49, 50, 51, 52, 53, 56, 58, 59, 61, 62, 63, 64 | |
| Limitations clearly discussed | 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63 | 22, 37 | Not clearly reported in 22, 37 |
| Generalisability of findings discussed | 1, 2, 6, 10, 15, 16, 17, 19, 20, 21, 28, 30, 31, 32, 33, 34, 35, 42, 53, 54, 60, 61 | 3, 4, 5, 7, 8, 9, 11 ,12, 13, 14, 18, 22, 23, 24, 25, 26, 27, 29, 36, 37, 38, 39, 40, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 55, 56, 57, 58, 59, 62, 63 |